Decitabine

Generic Name
Decitabine
Brand Names
Dacogen, Inqovi 5 Tablet Pack
Drug Type
Small Molecule
Chemical Formula
C8H12N4O4
CAS Number
2353-33-5
Unique Ingredient Identifier
776B62CQ27
Background

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment option...

Indication

Decitabine is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), as well as for MDS scored ...

Associated Conditions
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Associated Therapies
-
Clinical Trials
Related News

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

Phase 1
Terminated
Conditions
Leukemia
Interventions
Drug: Dasatinib
Drug: Decitabine
First Posted Date
2011-12-23
Last Posted Date
2020-10-22
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
32
Registration Number
NCT01498445
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

First Posted Date
2011-12-01
Last Posted Date
2020-10-27
Lead Sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Target Recruit Count
23
Registration Number
NCT01483690
Locations
🇺🇸

Seattle Children's Hospital, Seattle, Washington, United States

🇦🇺

Children's Hospital at Westmead, Westmead, New South Wales, Australia

🇦🇺

Sydney Children's Hospital, Sydney, Australia

and more 25 locations

Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia

First Posted Date
2011-08-22
Last Posted Date
2023-02-28
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
165
Registration Number
NCT01420926
Locations
🇺🇸

NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States

🇺🇸

East Carolina University, Greenville, North Carolina, United States

🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 50 locations

Decitabine for High-Risk Sickle Cell Disease

Phase 2
Completed
Conditions
Neutropenia
Sickle Cell Disease
Interventions
Drug: Decitabine
First Posted Date
2011-06-17
Last Posted Date
2017-03-01
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
10
Registration Number
NCT01375608
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)

Phase 1
Completed
Conditions
Acute Myeloid Leukemia
Interventions
Drug: plerixafor
Drug: decitabine
First Posted Date
2011-05-12
Last Posted Date
2018-07-02
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
71
Registration Number
NCT01352650
Locations
🇺🇸

Weill Cornell Medical College, New York, New York, United States

Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients

Phase 2
Terminated
Conditions
Myelodysplastic Syndrome
Interventions
Drug: Decitabine
First Posted Date
2011-04-12
Last Posted Date
2014-06-17
Lead Sponsor
Singapore General Hospital
Target Recruit Count
6
Registration Number
NCT01333449
Locations
🇸🇬

Singapore General Hospital, Singapore, Singapore

A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 3
Completed
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Sapacitabine
Drug: Decitabine
First Posted Date
2011-02-25
Last Posted Date
2022-06-22
Lead Sponsor
Cyclacel Pharmaceuticals, Inc.
Target Recruit Count
482
Registration Number
NCT01303796
Locations
🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

🇺🇸

The University of Chicago Medical Center, Chicago, Illinois, United States

🇺🇸

St. Francis Medical Group Oncology and Hematology Specialists, Indianapolis, Indiana, United States

and more 114 locations

Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML

First Posted Date
2011-01-17
Last Posted Date
2015-11-20
Lead Sponsor
Seoul St. Mary's Hospital
Target Recruit Count
19
Registration Number
NCT01277484
Locations
🇰🇷

Seoul St. Mary's Hospital, Seoul, Korea, Republic of

Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia

Phase 2
Completed
Conditions
Chronic Myelomonocytic Leukemia
Interventions
Drug: Decitabine
First Posted Date
2010-12-02
Last Posted Date
2018-06-25
Lead Sponsor
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Target Recruit Count
43
Registration Number
NCT01251627
Locations
🇮🇹

Divisione di Ematologia, Ospedale S.Gerardo di Monza, Monza, Italy

🇮🇹

Ospedale S.Maria della Misericordia, Perugia, Italy

🇮🇹

Ematologia, Ospedale SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

and more 18 locations

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Phase 2
Terminated
Conditions
Pediatric Acute Myelogenous Leukemia (AML)
Interventions
Drug: Decitabine
First Posted Date
2010-08-09
Last Posted Date
2022-06-28
Lead Sponsor
Eisai Inc.
Target Recruit Count
25
Registration Number
NCT01177540
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy